Skip to main content
Erschienen in: Current Hematologic Malignancy Reports 4/2017

31.07.2017 | CART and Immunotherapy (M Ruella, Section Editor)

Considerations in T Cell Therapy Product Development for B Cell Leukemia and Lymphoma Immunotherapy

verfasst von: Andrew D. Fesnak, Patrick J. Hanley, Bruce L. Levine

Erschienen in: Current Hematologic Malignancy Reports | Ausgabe 4/2017

Einloggen, um Zugang zu erhalten

Abstract

Based on laboratory and clinical research findings and investments in immunotherapy by many institutions in academia, government-funded laboratories, and industry, there is tremendous and deserved excitement in the field of cell and gene therapy. In particular, understanding of immune-mediated control of cancer has created opportunities to develop new forms of therapies based on engineered T cells. Unlike conventional drugs or biologics, the source material for these new therapies is collected from the patient or donor. The next step is commonly either enrichment to deplete unwanted cells, or methods to positively select T cells prior to polyclonal expansion or antigen-specific expansion. As the first generation of engineered T cell therapies have demonstrated proof of concept, the next stages of development will require the integration of automated technologies to enable more consistent manufacturing and the ability to produce therapies for more patients.
Literatur
1.
Zurück zum Zitat Greenberg P, Goodrich J, Riddell S. Adoptive immunotherapy of human cytomegalovirus infection: potential role in protection from disease progression. Transplant Proc. 1991;23(3 Suppl 3):97–101.PubMed Greenberg P, Goodrich J, Riddell S. Adoptive immunotherapy of human cytomegalovirus infection: potential role in protection from disease progression. Transplant Proc. 1991;23(3 Suppl 3):97–101.PubMed
2.
Zurück zum Zitat Riddell SR, Watanabe KS, Goodrich JM, Li CR, Agha ME, Greenberg PD. Restoration of viral immunity in immunodeficient humans by the adoptive transfer of T cell clones. Science. 1992;257(5067):238–41.CrossRefPubMed Riddell SR, Watanabe KS, Goodrich JM, Li CR, Agha ME, Greenberg PD. Restoration of viral immunity in immunodeficient humans by the adoptive transfer of T cell clones. Science. 1992;257(5067):238–41.CrossRefPubMed
3.
Zurück zum Zitat Riddell SR, Greenberg PD, Overell RW, Loughran TP, Gilbert MJ, Lupton SD, et al. Phase I study of cellular adoptive immunotherapy using genetically modified CD8+ HIV-specific T cells for HIV seropositive patients undergoing allogeneic bone marrow transplant. The Fred Hutchinson Cancer Research Center and the University of Washington School of Medicine, Department of Medicine, Division of Oncology. Hum Gene Ther. 1992;3(3):319–38. doi:10.1089/hum.1992.3.3-319.CrossRefPubMed Riddell SR, Greenberg PD, Overell RW, Loughran TP, Gilbert MJ, Lupton SD, et al. Phase I study of cellular adoptive immunotherapy using genetically modified CD8+ HIV-specific T cells for HIV seropositive patients undergoing allogeneic bone marrow transplant. The Fred Hutchinson Cancer Research Center and the University of Washington School of Medicine, Department of Medicine, Division of Oncology. Hum Gene Ther. 1992;3(3):319–38. doi:10.​1089/​hum.​1992.​3.​3-319.CrossRefPubMed
4.
Zurück zum Zitat Rooney CM, Smith CA, Ng CY, Loftin S, Li C, Krance RA, et al. Use of gene-modified virus-specific T lymphocytes to control Epstein-Barr-virus-related lymphoproliferation. Lancet. 1995;345(8941):9–13.CrossRefPubMed Rooney CM, Smith CA, Ng CY, Loftin S, Li C, Krance RA, et al. Use of gene-modified virus-specific T lymphocytes to control Epstein-Barr-virus-related lymphoproliferation. Lancet. 1995;345(8941):9–13.CrossRefPubMed
6.
Zurück zum Zitat Hanley PJ, Cruz CR, Savoldo B, Leen AM, Stanojevic M, Khalil M, et al. Functionally active virus-specific T cells that target CMV, adenovirus, and EBV can be expanded from naive T-cell populations in cord blood and will target a range of viral epitopes. Blood. 2009;114(9):1958–67. doi:10.1182/blood-2009-03-213256.CrossRefPubMedPubMedCentral Hanley PJ, Cruz CR, Savoldo B, Leen AM, Stanojevic M, Khalil M, et al. Functionally active virus-specific T cells that target CMV, adenovirus, and EBV can be expanded from naive T-cell populations in cord blood and will target a range of viral epitopes. Blood. 2009;114(9):1958–67. doi:10.​1182/​blood-2009-03-213256.CrossRefPubMedPubMedCentral
7.
Zurück zum Zitat Hanley PJ, Lam S, Shpall EJ, Bollard CM. Expanding cytotoxic T lymphocytes from umbilical cord blood that target cytomegalovirus, Epstein-Barr virus, and adenovirus. J Vis Exp. 2012;63:e3627. doi:10.3791/3627. Hanley PJ, Lam S, Shpall EJ, Bollard CM. Expanding cytotoxic T lymphocytes from umbilical cord blood that target cytomegalovirus, Epstein-Barr virus, and adenovirus. J Vis Exp. 2012;63:e3627. doi:10.​3791/​3627.
10.
Zurück zum Zitat Weber G, Gerdemann U, Caruana I, Savoldo B, Hensel NF, Rabin KR, et al. Generation of multi-leukemia antigen-specific T cells to enhance the graft-versus-leukemia effect after allogeneic stem cell transplant. Leukemia. 2013;27(7):1538–47. doi:10.1038/leu.2013.66.CrossRefPubMed Weber G, Gerdemann U, Caruana I, Savoldo B, Hensel NF, Rabin KR, et al. Generation of multi-leukemia antigen-specific T cells to enhance the graft-versus-leukemia effect after allogeneic stem cell transplant. Leukemia. 2013;27(7):1538–47. doi:10.​1038/​leu.​2013.​66.CrossRefPubMed
11.
Zurück zum Zitat Williams KM, Grant M, Ismail M, Hoq F, Martin-Manso M, Hoover J, et al. Complete remissions post infusion of multiple tumor antigen specific T cells for the treatment of high risk leukemia and lymphoma patients after HCT. Cytotherapy. 2017;19(5, Supplement):e3. doi:10.1016/j.jcyt.2017.03.013.CrossRef Williams KM, Grant M, Ismail M, Hoq F, Martin-Manso M, Hoover J, et al. Complete remissions post infusion of multiple tumor antigen specific T cells for the treatment of high risk leukemia and lymphoma patients after HCT. Cytotherapy. 2017;19(5, Supplement):e3. doi:10.​1016/​j.​jcyt.​2017.​03.​013.CrossRef
12.
Zurück zum Zitat Gross G, Waks T, Eshhar Z. Expression of immunoglobulin-T-cell receptor chimeric molecules as functional receptors with antibody-type specificity. Proc Natl Acad Sci U S A. 1989;86(24):10024–8.CrossRefPubMedPubMedCentral Gross G, Waks T, Eshhar Z. Expression of immunoglobulin-T-cell receptor chimeric molecules as functional receptors with antibody-type specificity. Proc Natl Acad Sci U S A. 1989;86(24):10024–8.CrossRefPubMedPubMedCentral
13.
Zurück zum Zitat Kuwana Y, Asakura Y, Utsunomiya N, Nakanishi M, Arata Y, Itoh S, et al. Expression of chimeric receptor composed of immunoglobulin-derived V regions and T-cell receptor-derived C regions. Biochem Biophys Res Commun. 1987;149(3):960–8.CrossRefPubMed Kuwana Y, Asakura Y, Utsunomiya N, Nakanishi M, Arata Y, Itoh S, et al. Expression of chimeric receptor composed of immunoglobulin-derived V regions and T-cell receptor-derived C regions. Biochem Biophys Res Commun. 1987;149(3):960–8.CrossRefPubMed
14.
15.
Zurück zum Zitat Mitsuyasu RT, Anton PA, Deeks SG, Scadden DT, Connick E, Downs MT, et al. Prolonged survival and tissue trafficking following adoptive transfer of CD4zeta gene-modified autologous CD4(+) and CD8(+) T cells in human immunodeficiency virus-infected subjects. Blood. 2000;96(3):785–93.PubMed Mitsuyasu RT, Anton PA, Deeks SG, Scadden DT, Connick E, Downs MT, et al. Prolonged survival and tissue trafficking following adoptive transfer of CD4zeta gene-modified autologous CD4(+) and CD8(+) T cells in human immunodeficiency virus-infected subjects. Blood. 2000;96(3):785–93.PubMed
16.
Zurück zum Zitat Walker RE, Bechtel CM, Natarajan V, Baseler M, Hege KM, Metcalf JA, et al. Long-term in vivo survival of receptor-modified syngeneic T cells in patients with human immunodeficiency virus infection. Blood. 2000;96(2):467–74.PubMed Walker RE, Bechtel CM, Natarajan V, Baseler M, Hege KM, Metcalf JA, et al. Long-term in vivo survival of receptor-modified syngeneic T cells in patients with human immunodeficiency virus infection. Blood. 2000;96(2):467–74.PubMed
18.
Zurück zum Zitat Kochenderfer JN, Dudley ME, Feldman SA, Wilson WH, Spaner DE, Maric I, et al. B-cell depletion and remissions of malignancy along with cytokine-associated toxicity in a clinical trial of anti-CD19 chimeric-antigen-receptor-transduced T cells. Blood. 2012;119(12):2709–20. doi:10.1182/blood-2011-10-384388.CrossRefPubMedPubMedCentral Kochenderfer JN, Dudley ME, Feldman SA, Wilson WH, Spaner DE, Maric I, et al. B-cell depletion and remissions of malignancy along with cytokine-associated toxicity in a clinical trial of anti-CD19 chimeric-antigen-receptor-transduced T cells. Blood. 2012;119(12):2709–20. doi:10.​1182/​blood-2011-10-384388.CrossRefPubMedPubMedCentral
23.
Zurück zum Zitat Hexner EO, Luger SM, Reshef R, Jeschke GR, Mangan JK, Frey NV, et al. Infusion of CD3/CD28 costimulated umbilical cord blood T cells at the time of single umbilical cord blood transplantation may enhance engraftment. Am J Hematol. 2016;91(5):453–60. doi:10.1002/ajh.24303.CrossRefPubMed Hexner EO, Luger SM, Reshef R, Jeschke GR, Mangan JK, Frey NV, et al. Infusion of CD3/CD28 costimulated umbilical cord blood T cells at the time of single umbilical cord blood transplantation may enhance engraftment. Am J Hematol. 2016;91(5):453–60. doi:10.​1002/​ajh.​24303.CrossRefPubMed
25.
Zurück zum Zitat •• Singh N, Perazzelli J, Grupp SA, Barrett DM. Early memory phenotypes drive T cell proliferation in patients with pediatric malignancies. Sci Transl Med. 2016;8(320):320ra3. doi:10.1126/scitranslmed.aad5222. Demonstrates treatment-related expansion defects of benign T cells in patients with acute lymphoblastic leukemia, suggesting that T cell manufacturing from these patients may be limited by prior treatment CrossRefPubMed •• Singh N, Perazzelli J, Grupp SA, Barrett DM. Early memory phenotypes drive T cell proliferation in patients with pediatric malignancies. Sci Transl Med. 2016;8(320):320ra3. doi:10.​1126/​scitranslmed.​aad5222. Demonstrates treatment-related expansion defects of benign T cells in patients with acute lymphoblastic leukemia, suggesting that T cell manufacturing from these patients may be limited by prior treatment CrossRefPubMed
26.
Zurück zum Zitat Barth MJ, Chu Y, Hanley PJ, Cairo MS. Immunotherapeutic approaches for the treatment of childhood, adolescent and young adult non-Hodgkin lymphoma. Br J Haematol. 2016;173(4):597–616. doi:10.1111/bjh.14078.CrossRefPubMed Barth MJ, Chu Y, Hanley PJ, Cairo MS. Immunotherapeutic approaches for the treatment of childhood, adolescent and young adult non-Hodgkin lymphoma. Br J Haematol. 2016;173(4):597–616. doi:10.​1111/​bjh.​14078.CrossRefPubMed
27.
Zurück zum Zitat Bollard CM, Gottschalk S, Torrano V, Diouf O, Ku S, Hazrat Y, et al. Sustained complete responses in patients with lymphoma receiving autologous cytotoxic T lymphocytes targeting Epstein-Barr virus latent membrane proteins. J Clin Oncol Off J Am Soc Clin Oncol. 2014;32(8):798–808. doi:10.1200/JCO.2013.51.5304.CrossRef Bollard CM, Gottschalk S, Torrano V, Diouf O, Ku S, Hazrat Y, et al. Sustained complete responses in patients with lymphoma receiving autologous cytotoxic T lymphocytes targeting Epstein-Barr virus latent membrane proteins. J Clin Oncol Off J Am Soc Clin Oncol. 2014;32(8):798–808. doi:10.​1200/​JCO.​2013.​51.​5304.CrossRef
30.
Zurück zum Zitat Kaur I, Zulovich JM, Gonzalez M, McGee KM, Ponweera N, Thandi D, et al. Comparison of two methodologies for the enrichment of mononuclear cells from thawed cord blood products: the automated Sepax system versus the manual Ficoll method. Cytotherapy. 2017;19(3):433–9. doi:10.1016/j.jcyt.2016.11.010.CrossRefPubMed Kaur I, Zulovich JM, Gonzalez M, McGee KM, Ponweera N, Thandi D, et al. Comparison of two methodologies for the enrichment of mononuclear cells from thawed cord blood products: the automated Sepax system versus the manual Ficoll method. Cytotherapy. 2017;19(3):433–9. doi:10.​1016/​j.​jcyt.​2016.​11.​010.CrossRefPubMed
31.
Zurück zum Zitat Powell DJ Jr, Brennan AL, Zheng Z, Huynh H, Cotte J, Levine BL. Efficient clinical-scale enrichment of lymphocytes for use in adoptive immunotherapy using a modified counterflow centrifugal elutriation program. Cytotherapy. 2009;11(7):923–35. doi:10.3109/14653240903188921.CrossRefPubMed Powell DJ Jr, Brennan AL, Zheng Z, Huynh H, Cotte J, Levine BL. Efficient clinical-scale enrichment of lymphocytes for use in adoptive immunotherapy using a modified counterflow centrifugal elutriation program. Cytotherapy. 2009;11(7):923–35. doi:10.​3109/​1465324090318892​1.CrossRefPubMed
34.
Zurück zum Zitat •• Bluestone JA, Buckner JH, Fitch M, Gitelman SE, Gupta S, Hellerstein MK, et al. Type 1 diabetes immunotherapy using polyclonal regulatory T cells. Sci Transl Med. 2015;7(315):315ra189. doi:10.1126/scitranslmed.aad4134. Demonstrates the feasibility of using FACS cell sorting to isolate therapeutic cell subsets (Tregs in this case) for clinical use CrossRefPubMedPubMedCentral •• Bluestone JA, Buckner JH, Fitch M, Gitelman SE, Gupta S, Hellerstein MK, et al. Type 1 diabetes immunotherapy using polyclonal regulatory T cells. Sci Transl Med. 2015;7(315):315ra189. doi:10.​1126/​scitranslmed.​aad4134. Demonstrates the feasibility of using FACS cell sorting to isolate therapeutic cell subsets (Tregs in this case) for clinical use CrossRefPubMedPubMedCentral
35.
Zurück zum Zitat • Turtle CJ, Hanafi LA, Berger C, Gooley TA, Cherian S, Hudecek M, et al. CD19 CAR-T cells of defined CD4+:CD8+ composition in adult B cell ALL patients. J Clin Invest. 2016;126(6):2123–38. doi:10.1172/JCI85309. Demonstrates a novel approach toward standardizing starting cellular material for therapeutic cell manufacturing and the associated improvement of clinical outcomes CrossRefPubMedPubMedCentral • Turtle CJ, Hanafi LA, Berger C, Gooley TA, Cherian S, Hudecek M, et al. CD19 CAR-T cells of defined CD4+:CD8+ composition in adult B cell ALL patients. J Clin Invest. 2016;126(6):2123–38. doi:10.​1172/​JCI85309. Demonstrates a novel approach toward standardizing starting cellular material for therapeutic cell manufacturing and the associated improvement of clinical outcomes CrossRefPubMedPubMedCentral
36.
Zurück zum Zitat • Fraietta JA, Lacey SF, Wilcox NS, Bedoya F, Chen F, Orlando E, Brogdon JL, Hwang WT, Frey N, Young RM, Pequignot E, Ambrose DE, Levine BL, Bitter H, Porter DL, Xu J, June CH, Melenhorst JJ. Biomarkers of response to anti-CD19 chimeric antigen receptor (CAR) T-cell therapy in patients with chronic lymphocytic leukemia. Blood. 2016;128(22). Demonstrates the ability to predict response to CD19 specific CAR T cells using biomarker signatures. • Fraietta JA, Lacey SF, Wilcox NS, Bedoya F, Chen F, Orlando E, Brogdon JL, Hwang WT, Frey N, Young RM, Pequignot E, Ambrose DE, Levine BL, Bitter H, Porter DL, Xu J, June CH, Melenhorst JJ. Biomarkers of response to anti-CD19 chimeric antigen receptor (CAR) T-cell therapy in patients with chronic lymphocytic leukemia. Blood. 2016;128(22). Demonstrates the ability to predict response to CD19 specific CAR T cells using biomarker signatures.
38.
Zurück zum Zitat •• Vera JF, Brenner LJ, Gerdemann U, Ngo MC, Sili U, Liu H, et al. Accelerated production of antigen-specific T cells for preclinical and clinical applications using gas-permeable rapid expansion cultureware (G-Rex). J Immunother. 2010;33(3):305–15. doi:10.1097/CJI.0b013e3181c0c3cb. This publication demonstrates the capability of the Grex device in augmenting cell expansion. It compares the manufacturing process of EBV-specific T cells expanded in 24-well plates and the Grex and evaluates criteria such as production hours, number of flasks, and final yield CrossRefPubMedPubMedCentral •• Vera JF, Brenner LJ, Gerdemann U, Ngo MC, Sili U, Liu H, et al. Accelerated production of antigen-specific T cells for preclinical and clinical applications using gas-permeable rapid expansion cultureware (G-Rex). J Immunother. 2010;33(3):305–15. doi:10.​1097/​CJI.​0b013e3181c0c3cb​. This publication demonstrates the capability of the Grex device in augmenting cell expansion. It compares the manufacturing process of EBV-specific T cells expanded in 24-well plates and the Grex and evaluates criteria such as production hours, number of flasks, and final yield CrossRefPubMedPubMedCentral
39.
Zurück zum Zitat Bunos M, Hummer C, Wingenfeld E, Sorg N, Pfirrmann V, Bader P, et al. Automated isolation of primary antigen-specific T cells from donor lymphocyte concentrates: results of a feasibility exercise. Vox Sang. 2015;109(4):387–93. doi:10.1111/vox.12291.CrossRefPubMed Bunos M, Hummer C, Wingenfeld E, Sorg N, Pfirrmann V, Bader P, et al. Automated isolation of primary antigen-specific T cells from donor lymphocyte concentrates: results of a feasibility exercise. Vox Sang. 2015;109(4):387–93. doi:10.​1111/​vox.​12291.CrossRefPubMed
40.
Zurück zum Zitat Kumaresan P, Figliola M, Moyes JS, Huls MH, Tewari P, Shpall EJ, et al. Automated cell enrichment of cytomegalovirus-specific T cells for clinical applications using the cytokine-capture system. J Vis Exp. 2015;104 doi:10.3791/52808. Kumaresan P, Figliola M, Moyes JS, Huls MH, Tewari P, Shpall EJ, et al. Automated cell enrichment of cytomegalovirus-specific T cells for clinical applications using the cytokine-capture system. J Vis Exp. 2015;104 doi:10.​3791/​52808.
42.
43.
Zurück zum Zitat Berger C, Jensen MC, Lansdorp PM, Gough M, Elliott C, Riddell SR. Adoptive transfer of effector CD8+ T cells derived from central memory cells establishes persistent T cell memory in primates. J Clin Invest. 2008;118(1):294–305. doi:10.1172/jci32103.CrossRefPubMed Berger C, Jensen MC, Lansdorp PM, Gough M, Elliott C, Riddell SR. Adoptive transfer of effector CD8+ T cells derived from central memory cells establishes persistent T cell memory in primates. J Clin Invest. 2008;118(1):294–305. doi:10.​1172/​jci32103.CrossRefPubMed
44.
Zurück zum Zitat Wang X, Popplewell LL, Wagner JR, Naranjo A, Blanchard MS, Mott MR, et al. Phase I studies of central-memory-derived CD19 CAR T cell therapy following autologous HSCT in patients with B-cell NHL. Blood. 2016; doi:10.1182/blood-2015-12-686725. Wang X, Popplewell LL, Wagner JR, Naranjo A, Blanchard MS, Mott MR, et al. Phase I studies of central-memory-derived CD19 CAR T cell therapy following autologous HSCT in patients with B-cell NHL. Blood. 2016; doi:10.​1182/​blood-2015-12-686725.
46.
Zurück zum Zitat Perna SK, De Angelis B, Pagliara D, Hasan ST, Zhang L, Mahendravada A, et al. Interleukin 15 provides relief to CTLs from regulatory T cell-mediated inhibition: implications for adoptive T cell-based therapies for lymphoma. Clin Cancer Res. 2013;19(1):106–17. doi:10.1158/1078-0432.ccr-12-2143.CrossRefPubMed Perna SK, De Angelis B, Pagliara D, Hasan ST, Zhang L, Mahendravada A, et al. Interleukin 15 provides relief to CTLs from regulatory T cell-mediated inhibition: implications for adoptive T cell-based therapies for lymphoma. Clin Cancer Res. 2013;19(1):106–17. doi:10.​1158/​1078-0432.​ccr-12-2143.CrossRefPubMed
47.
Zurück zum Zitat Perna SK, Pagliara D, Mahendravada A, Liu H, Brenner MK, Savoldo B, et al. Interleukin-7 mediates selective expansion of tumor-redirected cytotoxic T lymphocytes (CTLs) without enhancement of regulatory T-cell inhibition. Clin Cancer Res. 2014;20(1):131–9. doi:10.1158/1078-0432.ccr-13-1016.CrossRefPubMed Perna SK, Pagliara D, Mahendravada A, Liu H, Brenner MK, Savoldo B, et al. Interleukin-7 mediates selective expansion of tumor-redirected cytotoxic T lymphocytes (CTLs) without enhancement of regulatory T-cell inhibition. Clin Cancer Res. 2014;20(1):131–9. doi:10.​1158/​1078-0432.​ccr-13-1016.CrossRefPubMed
48.
50.
Zurück zum Zitat Bonyhadi M, Frohlich M, Rasmussen A, Ferrand C, Grosmaire L, Robinet E, et al. In vitro engagement of CD3 and CD28 corrects T cell defects in chronic lymphocytic leukemia. J Immunol. 2005;174(4):2366–75.CrossRefPubMed Bonyhadi M, Frohlich M, Rasmussen A, Ferrand C, Grosmaire L, Robinet E, et al. In vitro engagement of CD3 and CD28 corrects T cell defects in chronic lymphocytic leukemia. J Immunol. 2005;174(4):2366–75.CrossRefPubMed
51.
Zurück zum Zitat Ramsay AG, Johnson AJ, Lee AM, Gorgun G, Le Dieu R, Blum W, et al. Chronic lymphocytic leukemia T cells show impaired immunological synapse formation that can be reversed with an immunomodulating drug. J Clin Invest. 2008;118(7):2427–37. doi:10.1172/jci35017.PubMedPubMedCentral Ramsay AG, Johnson AJ, Lee AM, Gorgun G, Le Dieu R, Blum W, et al. Chronic lymphocytic leukemia T cells show impaired immunological synapse formation that can be reversed with an immunomodulating drug. J Clin Invest. 2008;118(7):2427–37. doi:10.​1172/​jci35017.PubMedPubMedCentral
53.
Zurück zum Zitat Ruella M, Kenderian SS, Shestova O, Fraietta JA, Qayyum S, Zhang Q, et al. The addition of the BTK inhibitor ibrutinib to anti-CD19 chimeric antigen receptor T cells (CART19) improves responses against mantle cell lymphoma. Clin Cancer Res. 2016;22(11):2684–96. doi:10.1158/1078-0432.ccr-15-1527.CrossRefPubMed Ruella M, Kenderian SS, Shestova O, Fraietta JA, Qayyum S, Zhang Q, et al. The addition of the BTK inhibitor ibrutinib to anti-CD19 chimeric antigen receptor T cells (CART19) improves responses against mantle cell lymphoma. Clin Cancer Res. 2016;22(11):2684–96. doi:10.​1158/​1078-0432.​ccr-15-1527.CrossRefPubMed
54.
56.
Zurück zum Zitat Lu TL, Pugach O, Somerville R, Rosenberg SA, Kochendefer JN, Better M, et al. A rapid cell expansion process for production of engineered autologous CAR-T cell therapies. Human gene therapy methods. 2016;27(6):209–18. doi:10.1089/hgtb.2016.120.CrossRefPubMed Lu TL, Pugach O, Somerville R, Rosenberg SA, Kochendefer JN, Better M, et al. A rapid cell expansion process for production of engineered autologous CAR-T cell therapies. Human gene therapy methods. 2016;27(6):209–18. doi:10.​1089/​hgtb.​2016.​120.CrossRefPubMed
57.
Zurück zum Zitat Frey NV, Shaw PA, Hexner EO, Gill S, Marcucci K, Luger SM, Mangan JK, Grupp SA, Maude SL, Ericson S. Optimizing chimeric antigen receptor (CAR) T cell therapy for adult patients with relapsed or refractory (r/r) acute lymphoblastic leukemia (ALL). American Society of Clinical Oncology; 2016. Frey NV, Shaw PA, Hexner EO, Gill S, Marcucci K, Luger SM, Mangan JK, Grupp SA, Maude SL, Ericson S. Optimizing chimeric antigen receptor (CAR) T cell therapy for adult patients with relapsed or refractory (r/r) acute lymphoblastic leukemia (ALL). American Society of Clinical Oncology; 2016.
58.
60.
Zurück zum Zitat Verhoeyen E, Dardalhon V, Ducrey-Rundquist O, Trono D, Taylor N, Cosset FL. IL-7 surface-engineered lentiviral vectors promote survival and efficient gene transfer in resting primary T lymphocytes. Blood. 2003;101(6):2167–74. doi:10.1182/blood-2002-07-2224.CrossRefPubMed Verhoeyen E, Dardalhon V, Ducrey-Rundquist O, Trono D, Taylor N, Cosset FL. IL-7 surface-engineered lentiviral vectors promote survival and efficient gene transfer in resting primary T lymphocytes. Blood. 2003;101(6):2167–74. doi:10.​1182/​blood-2002-07-2224.CrossRefPubMed
63.
Zurück zum Zitat Berdien B, Mock U, Atanackovic D, Fehse B. TALEN-mediated editing of endogenous T-cell receptors facilitates efficient reprogramming of T lymphocytes by lentiviral gene transfer. Gene Ther. 2014;21(6):539–48. doi:10.1038/gt.2014.26.CrossRefPubMed Berdien B, Mock U, Atanackovic D, Fehse B. TALEN-mediated editing of endogenous T-cell receptors facilitates efficient reprogramming of T lymphocytes by lentiviral gene transfer. Gene Ther. 2014;21(6):539–48. doi:10.​1038/​gt.​2014.​26.CrossRefPubMed
66.
Zurück zum Zitat Poirot L, Philip B, Schiffer-Mannioui C, Le Clerre D, Chion-Sotinel I, Derniame S, et al. Multiplex genome-edited T-cell manufacturing platform for “off-the-shelf” adoptive T-cell immunotherapies. Cancer Res. 2015;75(18):3853–64. doi:10.1158/0008-5472.CAN-14-3321.CrossRefPubMed Poirot L, Philip B, Schiffer-Mannioui C, Le Clerre D, Chion-Sotinel I, Derniame S, et al. Multiplex genome-edited T-cell manufacturing platform for “off-the-shelf” adoptive T-cell immunotherapies. Cancer Res. 2015;75(18):3853–64. doi:10.​1158/​0008-5472.​CAN-14-3321.CrossRefPubMed
67.
Zurück zum Zitat Ren J, Liu X, Fang C, Jiang S, June CH, Zhao Y. Multiplex Cripsr/Cas9 genome editing to generate potent universal CART and PD1-deficient cells against leukemia. Blood. 2015;126(23):4280. Ren J, Liu X, Fang C, Jiang S, June CH, Zhao Y. Multiplex Cripsr/Cas9 genome editing to generate potent universal CART and PD1-deficient cells against leukemia. Blood. 2015;126(23):4280.
Metadaten
Titel
Considerations in T Cell Therapy Product Development for B Cell Leukemia and Lymphoma Immunotherapy
verfasst von
Andrew D. Fesnak
Patrick J. Hanley
Bruce L. Levine
Publikationsdatum
31.07.2017
Verlag
Springer US
Erschienen in
Current Hematologic Malignancy Reports / Ausgabe 4/2017
Print ISSN: 1558-8211
Elektronische ISSN: 1558-822X
DOI
https://doi.org/10.1007/s11899-017-0395-9

Weitere Artikel der Ausgabe 4/2017

Current Hematologic Malignancy Reports 4/2017 Zur Ausgabe

CART and Immunotherapy (M Ruella, Section Editor)

Targeting Immune System Alterations in Hodgkin Lymphoma

B-cell NHL, T-cell NHL, and Hodgkin Lymphoma (D Persky, Section Editor)

An Update on the Use of Immunotherapy in the Treatment of Lymphoma

CART and Immunotherapy (M Ruella, Section Editor)

Novel Immunotherapies for Multiple Myeloma

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.